The Role of the Dermatologist in the Follow-up of Immune-Mediated Adverse Events

Center Mannheim were included D-dimers and differential blood counts were determined prospectively before the start of treatment and recorded sequentially every 3-6 weeks during treatment.TEEs were recorded and classified as thrombosis (e.g.deep vein thrombosis), apoplexy, pulmonary embolism or transient ischaemic attack.Results: Patients with an elevated D-dimer concentration in the blood (>0.6 mg/l) before the first cycle of ICI had a significantly higher risk of developing thromboembolic events during treatment.(Odds Ratio 4.3, p=0.0293)At the same time, patients with an elevated D-dimer concentration in the blood showed a reduced overall survival (OS) and a reduced progression-free survival (PFS).In addition, the D-dimer levels were assessed during ICI therapy.Conclusions: Patients with increased pro-coagulatory activity have a higher risk of thromboembolic events during ICI therapy, and at the same time this pro-coagulatory activity is associated with a poorer prognosis.Markers of coagulation activity, such as the concentration of Ddimers in the blood, could be used as promising biomarkers for the occurrence of TEE as well as for the prognosis under ICI therapy.